Enlivex Therapeutics Ltd
ENLV
View Detailed Chart
1.000USD
-0.030-2.92%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
23.86MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.92%
5 Days
-7.42%
1 Month
-5.67%
6 Months
-3.86%
Year to Date
-14.54%
1 Year
-23.08%
View Detailed Chart
TradingKey Stock Score of Enlivex Therapeutics Ltd
Currency: USD Updated: 2025-11-04Key Insights
The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows weak stock market performance, in line with its weak fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Enlivex Therapeutics Ltd's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
10.000
Target Price
+852.38%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Enlivex Therapeutics Ltd Highlights
StrengthsRisks
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Fairly Valued
The company’s latest PE is -1.78, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.83M shares, decreasing 15.56% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 168.39K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 5.81.
Enlivex Therapeutics Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Enlivex Therapeutics Ltd Info
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Ticker SymbolENLV
CompanyEnlivex Therapeutics Ltd
CEODr. Oren Hershkovitz, Ph.D.
Websitehttps://www.enlivex.com/
Related Instruments
+2.14%
-0.45%
+0.42%
-1.07%
+0.39%
+0.64%
+7.81%
+0.44%
-0.34%
+1.38%
-0.22%
-1.11%
+0.45%
+1.92%
-0.26%
-0.11%
0.00%
+2.58%
+2.62%
-3.14%Popular Symbols
